Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04679909 | Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) | PHASE1 | COMPLETED | 92 | — | — | Feb 25, 2021 | Dec 21, 2022 | Aug 14, 2023 | 6 | United States |
Counts and percentages of subjects with local and systemic events
Counts and percentages of subjects with AEs
| Arm | Type | Description |
|---|---|---|
| Single Low Dose AdCOVID | EXPERIMENTAL | - |
| Single Medium Dose AdCOVID | EXPERIMENTAL | - |
| Single High Dose AdCOVID | EXPERIMENTAL | - |
| Two Low Doses AdCOVID | EXPERIMENTAL | - |
| Two Medium Doses AdCOVID | EXPERIMENTAL | - |
| Two High Doses AdCOVID | EXPERIMENTAL | - |
| Single Dose Placebo | PLACEBO_COMPARATOR | - |
| Two Dose Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AdCOVID | BIOLOGICAL | Administered intranasally |
| Placebo | OTHER | Administered intranasally |
Inclusion Criteria: * Men and women ages 18 to 55 years, inclusive * Good general health status * Screening laboratory results within institutional normal range or Grade 1 abnormality if the Investigator documents clinical insignificance. Grade 2 laboratories may be permissible if considered not cl...